Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma

Tafasitamab (MOR208), an Fc-modified, humanized, anti-CD19 monoclonal antibody, combined with the immunomodulatory drug lenalidomide was clinically active with a good tolerability profile in the open-label, single-arm, phase II L-MIND study of patients with relapsed/refractory diffuse large B-cell l...

Descripción completa

Detalles Bibliográficos
Autores principales: Duell, Johannes, Maddocks, Kami J., González-Barca, Eva, Jurczak, Wojciech, Liberati, Anna Marina, de Vos, Sven, Nagy, Zsolt, Obr, Aleš, Gaidano, Gianluca, Abrisqueta, Pau, Kalakonda, Nagesh, André, Marc, Dreyling, Martin, Menne, Tobias, Tournilhac, Olivier, Augustin, Marinela, Rosenwald, Andreas, Dirnberger-Hertweck, Maren, Weirather, Johannes, Ambarkhane, Sumeet, Salles, Gilles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409029/
https://www.ncbi.nlm.nih.gov/pubmed/34196165
http://dx.doi.org/10.3324/haematol.2020.275958

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409029/
https://www.ncbi.nlm.nih.gov/pubmed/34196165
http://dx.doi.org/10.3324/haematol.2020.275958

Ejemplares similares